Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01431898 · ClinicalTrials.gov registry record · Phase 1
Safety, Tolerability, Pharmacokinetics and Antiviral Activity of GS-9669 in Subjects With Chronic Hepatitis C Virus Infection
A Phase 1 study, sponsored by Gilead Sciences.
- Completed
- Registry status
- Phase 1
- Development phase
- 82
- Enrollment target
NCT01431898 is a Phase 1 study that has completed, run by Gilead Sciences. The registered enrollment target is 82 participants.
The verdict
NCT01431898, a Phase 1 study, has completed, sponsored by Gilead Sciences.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 82 participants
- Enrollment target
Study Summary
This is a research study to evaluate the safety, tolerability and anti-viral activity of GS-9669 in patients with Hepatitis C infection.
Interventions
- DRUG GS-9669 tablets
- DRUG Placebo to Match GS-9669 tablet
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 82 participants |
| Start Date | 2011-09 |
| Est. Completion | 2012-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01431898
The ClinicalTrials.gov registry entry for NCT01431898 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 82 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which GS-9669 tablets is the first listed.
NCT01431898 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01431898 about?
NCT01431898 is a clinical study titled "Safety, Tolerability, Pharmacokinetics and Antiviral Activity of GS-9669 in Subjects With Chronic Hepatitis C Virus Infection". This is a research study to evaluate the safety, tolerability and anti-viral activity of GS-9669 in patients with Hepatitis C infection.
What is the current status of trial NCT01431898?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 82 participants. The study started on 2011-09. Estimated completion is 2012-05.
What interventions are being tested in trial NCT01431898?
The interventions under investigation include: GS-9669 tablets (DRUG), Placebo to Match GS-9669 tablet (DRUG).
Who is sponsoring clinical trial NCT01431898?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.